Literature DB >> 19305160

Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU).

Eleanor J Whitford1, Adrian G Cummins, Ross N Butler, Luca D Prisciandaro, Jane K Fauser, Roger Yazbeck, Andrew Lawrence, Ker Y Cheah, Tessa H Wright, Kerry A Lymn, Gordon S Howarth.   

Abstract

Beneficial bacteria (probiotics) and probiotic-derived factors have the potential to ameliorate disorders of the intestine. The aim of this study was to compare live Streptococcus thermophilus TH-4 (TH-4), dead TH-4 and TH-4 supernatant in rats treated with 5-Fluorouracil. Rats were randomly allocated to five treatment groups (n=8-10): Saline+Water; 5-FU+Skim Milk; 5-FU+Live TH-4; 5-FU+Supernatant TH-4; and 5-FU+Dead TH-4. 5-FU (150mg.kg(-1)) was administered by a single intraperitoneal injection on day 0; animals were killed on day 4. Treatments were administered daily from days -2 to 3 via oro-gastric gavage. Metabolic parameters were measured daily. Blood was obtained by cardiac puncture, and intestinal tissues removed for quantitative and qualitative histological assessment, including: villous height and area; crypt depth and area, mitotic count and crypt fission; biochemical determination of sucrase and myeloperoxidase (MPO) activity; and disease severity scoring. One-way ANOVA statistical analyses were conducted for the majority of outcome measures. Live TH-4 significantly reduced disease severity score by 13% (p< 0.05), and partially normalised mitotic counts compared with 5-FU+Skim milk controls. Live and supernatant TH-4 reduced crypt fission by 69% and 48% (p< 0.05), respectively, compared to 5-FU+Skim Milk controls. No significant differences (p> 0.05) in the occurrence of bacteraemia were evident across all groups. Live TH-4 partially normalised mitotic count and histological severity score in 5-FU treated rats. The inhibitory effect of live TH-4 and TH-4 supernatant on crypt fission suggests therapeutic utility in the prevention of disorders characterised by increased crypt fission, such as colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19305160

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  14 in total

1.  Using the noninvasive (13)C-sucrose breath test to measure intestinal sucrase activity in swine.

Authors:  Robyn Terry; William H E J van Wettere; Alexandra L Whittaker; Paul J Herde; Gordon S Howarth
Journal:  Comp Med       Date:  2012-12       Impact factor: 0.982

2.  A diet containing whey protein, glutamine, and TGFbeta modulates gut protein metabolism during chemotherapy-induced mucositis in rats.

Authors:  Nabile Boukhettala; Ayman Ibrahim; Sophie Claeyssens; Magali Faure; Florence Le Pessot; Jacques Vuichoud; Alain Lavoinne; Denis Breuillé; Pierre Déchelotte; Moïse Coëffier
Journal:  Dig Dis Sci       Date:  2009-11-13       Impact factor: 3.199

3.  In vivo effects of immunomodulators in a murine model of Fluorouracil-induced mucositis.

Authors:  David Tung; Peter H Cheung; Gregory Tudor; Catherine Booth; Saurabh Saha
Journal:  Curr Ther Res Clin Exp       Date:  2011-12

Review 4.  Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis.

Authors:  Rodrigo D De Oliveira Carvalho; Fillipe L R do Carmo; Alberto de Oliveira Junior; Philippe Langella; Jean-Marc Chatel; Luis G Bermúdez-Humarán; Vasco Azevedo; Marcela S de Azevedo
Journal:  Front Microbiol       Date:  2017-05-09       Impact factor: 5.640

5.  Depletion of enteric bacteria diminishes leukocyte infiltration following doxorubicin-induced small intestinal damage in mice.

Authors:  Jacquelyn S Carr; Stephanie King; Christopher M Dekaney
Journal:  PLoS One       Date:  2017-03-03       Impact factor: 3.240

Review 6.  Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.

Authors:  Concetta Panebianco; Angelo Andriulli; Valerio Pazienza
Journal:  Microbiome       Date:  2018-05-22       Impact factor: 14.650

Review 7.  Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities.

Authors:  Mansour Sedighi; Abed Zahedi Bialvaei; Michael R Hamblin; Elnaz Ohadi; Arezoo Asadi; Masoumeh Halajzadeh; Vahid Lohrasbi; Nima Mohammadzadeh; Taghi Amiriani; Marcela Krutova; Abolfazl Amini; Ebrahim Kouhsari
Journal:  Cancer Med       Date:  2019-04-05       Impact factor: 4.452

8.  Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model.

Authors:  Chun-Yan Yeung; Wai-Tao Chan; Chun-Bin Jiang; Mei-Lien Cheng; Chia-Yuan Liu; Szu-Wen Chang; Jen-Shiu Chiang Chiau; Hung-Chang Lee
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

9.  Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice.

Authors:  Tatiani Uceli Maioli; Brenda de Melo Silva; Michelle Nobre Dias; Nivea Carolina Paiva; Valbert Nascimento Cardoso; Simone Odilia Fernandes; Cláudia Martins Carneiro; Flaviano Dos Santos Martins; Simone de Vasconcelos Generoso
Journal:  J Negat Results Biomed       Date:  2014-04-11

10.  Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP.

Authors:  Rodrigo Carvalho; Aline Vaz; Felipe Luiz Pereira; Fernanda Dorella; Eric Aguiar; Jean-Marc Chatel; Luis Bermudez; Philippe Langella; Gabriel Fernandes; Henrique Figueiredo; Aristóteles Goes-Neto; Vasco Azevedo
Journal:  Sci Rep       Date:  2018-10-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.